Education
About Us
Working with TipRanks
Follow Us
Emmaus Life Sciences Inc (EMMA)
OTHER OTC:EMMA
RESEARCH TOOLSreports
Total Valuation
Emmaus Life Sciences has a market cap or net worth of $957.98K. The enterprise value is $100.96M.
Market Cap$957.98K
Enterprise Value$100.96M
Share Statistics
Emmaus Life Sciences has 63,865,570 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding63,865,570
Owned by Insiders―
Owned by Institutions―
Financial Efficiency
Emmaus Life Sciences’s return on equity (ROE) is 0.11 and return on invested capital (ROIC) is 19.24%.
Return on Equity (ROE)0.11
Return on Assets (ROA)-0.27
Return on Invested Capital (ROIC)19.24%
Return on Capital Employed (ROCE)0.05
Revenue Per Employee489.79K
Profits Per Employee-189.79K
Employee Count34
Asset Turnover0.71
Inventory Turnover0.73
Valuation Ratios
The current PE Ratio of Emmaus Life Sciences is -0.08. Emmaus Life Sciences’s PEG ratio is 0.04.
PE Ratio-0.08
PS Ratio0.00
PB Ratio-0.38
Price to Fair Value>-0.01
Price to FCF-2.52
Price to Operating Cash Flow-2.54
PEG Ratio0.04
Income Statement
In the last 12 months, Emmaus Life Sciences had revenue of 16.65M and earned -6.45M in profits. Earnings per share was -0.10.
Revenue16.65M
Gross Profit15.45M
Operating Income-1.89M
Pretax Income-6.42M
Net Income-6.45M
EBITDA-910.00K
Earnings Per Share (EPS)-0.10
Cash Flow
In the last 12 months, operating cash flow was -2.15M and capital expenditures -8.00K, giving a free cash flow of -2.15M billion.
Operating Cash Flow-2.15M
Free Cash Flow-2.15M
Free Cash Flow per Share-0.03
Dividends & Yields
Emmaus Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta54.28
52-Week Price Change-88.89%
50-Day Moving Average0.02
200-Day Moving Average0.03
Relative Strength Index (RSI)18.03
Average Volume (3m)17.78K
Important Dates
Emmaus Life Sciences upcoming earnings date is Aug 18, 2025, Before Open (Confirmed).
Last Earnings DateMay 15, 2025
Next Earnings DateAug 18, 2025
Ex-Dividend Date―
Financial Position
Emmaus Life Sciences as a current ratio of 0.11, with Debt / Equity ratio of -73.62%
Current Ratio0.11
Quick Ratio0.08
Debt to Market Cap60.11
Net Debt to EBITDA-34.87
Interest Coverage Ratio-0.34
Taxes
In the past 12 months, Emmaus Life Sciences has paid 29.00K in taxes.
Income Tax29.00K
Effective Tax Rate>-0.01
Enterprise Valuation
Emmaus Life Sciences EV to EBITDA ratio is -35.47, with an EV/FCF ratio of -14.04.
EV to Sales1.94
EV to EBITDA-35.47
EV to Free Cash Flow-14.04
EV to Operating Cash Flow-14.12
Balance Sheet
Emmaus Life Sciences has $1.33M in cash and marketable securities with $32.98M in debt, giving a net cash position of $31.64M billion.
Cash & Marketable Securities$1.33M
Total Debt$32.98M
Net Cash$31.64M
Net Cash Per Share$0.50
Tangible Book Value Per Share-$0.89
Margins
Gross margin is 85.93%, with operating margin of -11.37%, and net profit margin of -38.75%.
Gross Margin85.93%
Operating Margin-11.37%
Pretax Margin-38.58%
Net Profit Margin-38.75%
EBITDA Margin-5.46%
EBIT Margin-5.60%
Analyst Forecast
The average price target for Emmaus Life Sciences is ―, which is 11.43% higher than the current price. The consensus rating is ―
Price Target―
Price Target Upside―
Analyst Consensus―
Analyst Count0
Revenue Growth Forecast-34.70%
EPS Growth Forecast10.06%